| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 08/01/2025 | 13:00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CGEN | Compugen Ltd |
| 08/01/2025 | 13:00 | PR Newswire (US) | Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors | NASDAQ:CGEN | Compugen Ltd |
| 27/11/2024 | 13:00 | PR Newswire (US) | Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies | NASDAQ:CGEN | Compugen Ltd |
| 12/11/2024 | 13:00 | PR Newswire (US) | Compugen Reports Third Quarter 2024 Results | NASDAQ:CGEN | Compugen Ltd |
| 11/11/2024 | 13:00 | PR Newswire (US) | Compugen to Participate in Stifel 2024 Healthcare Conference | NASDAQ:CGEN | Compugen Ltd |
| 05/11/2024 | 15:00 | PR Newswire (US) | Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 | NASDAQ:CGEN | Compugen Ltd |
| 29/10/2024 | 12:00 | PR Newswire (US) | Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 | NASDAQ:CGEN | Compugen Ltd |
| 07/10/2024 | 13:00 | PR Newswire (US) | Compugen to Present New Clinical Data at SITC 2024 | NASDAQ:CGEN | Compugen Ltd |
| 09/09/2024 | 13:00 | PR Newswire (US) | Compugen to Present at Single Cell Genomics 2024 Conference | NASDAQ:CGEN | Compugen Ltd |
| 29/08/2024 | 13:00 | PR Newswire (US) | Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference | NASDAQ:CGEN | Compugen Ltd |
| 06/08/2024 | 13:00 | PR Newswire (US) | Compugen Reports Second Quarter 2024 Results | NASDAQ:CGEN | Compugen Ltd |
| 29/07/2024 | 13:00 | PR Newswire (US) | Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors | NASDAQ:CGEN | Compugen Ltd |
| 23/07/2024 | 13:00 | PR Newswire (US) | Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 | NASDAQ:CGEN | Compugen Ltd |
| 17/06/2024 | 13:00 | PR Newswire (US) | Compugen to Present at Upcoming Antibody Industrial Symposium | NASDAQ:CGEN | Compugen Ltd |
| 30/05/2024 | 13:00 | PR Newswire (US) | Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig | NASDAQ:CGEN | Compugen Ltd |
| 20/05/2024 | 13:00 | PR Newswire (US) | Compugen Reports First Quarter 2024 Results | NASDAQ:CGEN | Compugen Ltd |
| 20/05/2024 | 12:59 | IH Market News | U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip | NASDAQ:CGEN | Compugen Ltd |
| 16/05/2024 | 13:00 | PR Newswire (US) | Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential | NASDAQ:CGEN | Compugen Ltd |
| 15/05/2024 | 13:00 | PR Newswire (US) | Compugen Appoints David Silberman as Chief Financial Officer | NASDAQ:CGEN | Compugen Ltd |
| 06/05/2024 | 13:00 | PR Newswire (US) | Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 | NASDAQ:CGEN | Compugen Ltd |
| 25/04/2024 | 13:00 | PR Newswire (US) | Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 | NASDAQ:CGEN | Compugen Ltd |
| 10/04/2024 | 13:00 | PR Newswire (US) | Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 | NASDAQ:CGEN | Compugen Ltd |
| 03/04/2024 | 13:00 | PR Newswire (US) | Compugen to Participate in Two Upcoming Investor Conferences | NASDAQ:CGEN | Compugen Ltd |
| 11/03/2024 | 12:00 | PR Newswire (US) | Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy | NASDAQ:CGEN | Compugen Ltd |
| 06/03/2024 | 13:00 | PR Newswire (US) | Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 | NASDAQ:CGEN | Compugen Ltd |
| 05/03/2024 | 22:06 | Edgar (US Regulatory) | Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | NASDAQ:CGEN | Compugen Ltd |
| 05/03/2024 | 13:00 | PR Newswire (US) | Compugen Reports Fourth Quarter and Full Year 2023 Results | NASDAQ:CGEN | Compugen Ltd |
| 05/03/2024 | 12:05 | IH Market News | U.S. Futures Dip, Crude Oil Fluctuates | NASDAQ:CGEN | Compugen Ltd |
| 26/02/2024 | 13:00 | PR Newswire (US) | Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 | NASDAQ:CGEN | Compugen Ltd |
| 20/02/2024 | 13:00 | PR Newswire (US) | Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 | NASDAQ:CGEN | Compugen Ltd |